We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AbbVie’s Humira, Six Other Drugs Saw Unsupported Price Hikes in 2020, ICER Says
AbbVie’s Humira, Six Other Drugs Saw Unsupported Price Hikes in 2020, ICER Says
AbbVie’s rheumatoid arthritis drug Humira (adalimumab) and six other drugs whose prices were raised in 2020 without supportive clinical data cost the U.S. health system $1.67 billion in annual drug spending, according to a new analysis released yesterday by the Institute for Clinical and Economic Review (ICER).